Feline Insulinoma (Pancreatic Beta-Cell Tumor)

Feline insulinoma is a rare, functional neoplasm arising from the pancreatic beta cells (islets of Langerhans), characterized by autonomous, excessive secretion of insulin independent of blood glucose regulation [1][7]. This unregulated insulin production leads to persistent or episodic hypoglycemia, which drives the characteristic clinical syndrome [3]. While insulinoma is well-recognized and relatively more common in dogs and humans, it remains an uncommon but increasingly reported diagnosis in cats, with the majority of published cases occurring in middle-aged to older animals [2]. The tumor may be solitary or multifocal, benign or malignant, and its biological behavior in cats carries important implications for treatment planning and long-term prognosis [2][7].

Tumor Origin and Nature

Insulinoma arises from the neoplastic transformation of pancreatic beta cells, which normally produce and secrete insulin in direct response to blood glucose concentrations [1][7]. In neoplastic beta cells, the normal glucose-sensing and feedback mechanisms are disrupted, resulting in constitutive (autonomous) insulin secretion that is largely uncoupled from physiologic glucose levels [7].

Molecular and Cellular Basis

Molecular characterization of feline insulinoma has demonstrated that tumor cells retain immunohistochemical expression of insulin and other peptide hormones associated with islet cell function [7]. RT-PCR analysis of one well-characterized feline insulinoma showed expression of genes involved in glucose metabolism and insulin secretion, confirming functional autonomy at the cellular level [7]. The precise oncogenic mutations responsible for malignant transformation in cats have not been fully elucidated, and the molecular pathogenesis appears to differ from that in humans, where mutations in MEN1, DAXX/ATRX, and mTOR pathway genes are recognized drivers [7].

Pathophysiological Cascade

The downstream consequence of excess insulin secretion is persistent or recurrent hypoglycemia. When blood glucose falls below approximately 60–70 mg/dL, counter-regulatory hormones (glucagon, epinephrine, cortisol, growth hormone) are released, producing adrenergic signs (trembling, tachycardia). When glucose falls further—below approximately 40–50 mg/dL—neuroglycopenia develops, causing seizures, altered consciousness, and, if prolonged, irreversible neuronal injury [3][4]. The brain is almost entirely dependent on glucose as a fuel source, explaining the severity of neurological manifestations [3].

Tumor Characteristics

In cats, insulinomas are commonly found in the left lobe of the pancreas, though any part of the gland may be affected [3][5]. Tumors may be solitary or multiple, small and grossly inapparent, or forming palpable masses [2][6]. Histologically, they may be classified as benign adenomas or malignant carcinomas; malignant insulinomas may metastasize to regional lymph nodes, liver, and other abdominal organs [2]. The proportion of malignant versus benign tumors in cats is not definitively established, but metastatic disease at the time of diagnosis has been documented in a significant subset of surgical cases [2].

The diagnosis of feline insulinoma rests on demonstrating inappropriate hyperinsulinemia in the context of documented hypoglycemia, combined with compatible clinical signs and supportive imaging findings [3][4][6].

Step 1: Documentation of Hypoglycemia

• ·Fasting blood glucose is consistently or episodically low, typically below 60–70 mg/dL and often below 50 mg/dL during symptomatic episodes [3][4]
• ·Repeated glucose measurements are advisable, as hypoglycemia may be intermittent early in the disease course [3]

Step 2: Amended Insulin-to-Glucose Ratio (AIGR) / Serum Insulin Measurement

• ·The hallmark biochemical finding is an inappropriately elevated or even "normal" serum insulin concentration concurrent with documented hypoglycemia [3][4]
• ·In one reported case, insulin was measured at 1.78 ng/mL (reference interval 0.27–0.69 ng/mL) when blood glucose was 49 mg/dL, confirming functional insulin excess [4]
• ·In another case, insulin was within normal range (171 pmol/L) despite severe hypoglycemia (1.83 mmol/L), highlighting that even "normal" insulin is inappropriate at low glucose concentrations [3]
• ·Calculation of the amended insulin-to-glucose ratio (AIGR) can support the diagnosis when absolute insulin elevation is absent [3]

Standard Serum Biochemistry Panel — Relevant Indicators:

Step 3: Imaging

• ·Abdominal ultrasonography: Can identify pancreatic nodules or masses; described as the first modality to detect and characterize a feline insulinoma noninvasively [5]. Ultrasonography revealed a nodule in the left pancreatic lobe in one confirmed case, enabling presurgical planning [5].
• ·Computed tomography (CT): Dynamic (contrast-enhanced) CT provides superior anatomic detail and may identify multiple lesions as well as metastatic disease. In one feline case, CT revealed two pancreatic masses with different enhancement patterns during the late arterial phase, which proved critical in distinguishing insulinoma from mimicking lesions (e.g., intrapancreatic accessory spleen) [6].
• ·CT characteristics: Insulinomas typically show enhancement during the late arterial phase on dynamic CT, though enhancement patterns can overlap with other pancreatic masses [6].

Step 4: Histopathology (Definitive Diagnosis)

• ·Surgical excision or biopsy with histopathological examination remains the gold standard for definitive diagnosis and for distinguishing benign from malignant tumors [2][3]
• ·Immunohistochemistry for insulin expression confirms the beta-cell origin [7]

Key Differential Diagnoses to Exclude:

• ·Hepatic disease (portosystemic shunting, hepatic failure)
• ·Sepsis-associated hypoglycemia
• ·Hypoadrenocorticism
• ·Iatrogenic insulin overdose
• ·Intrapancreatic accessory spleen (can mimic insulinoma on imaging) [6]
• ·Other pancreatic masses (adenocarcinoma, pancreatitis-associated nodules)

Management of feline insulinoma is directed at controlling hypoglycemia and, where feasible, reducing tumor burden. Both surgical and medical approaches are employed [2][3][4].

Surgical Treatment (First-Line for Eligible Patients)

Partial pancreatectomy is the treatment of choice for localized disease and offers the best opportunity for long-term disease control [2][3]:

• ·Surgical excision of the tumor-bearing pancreatic lobe (most commonly the left lobe) is performed via exploratory laparotomy [2][3][5]
• ·The entire pancreas should be carefully palpated for additional nodules, and regional lymph nodes and the liver should be examined for metastatic lesions [2]
• ·In one retrospective surgical series of 20 cats, surgical excision was associated with a meaningful disease-free interval in a subset of patients [2]
• ·Potential surgical complications include pancreatitis, diabetes mellitus (from loss of normal islet tissue), hemorrhage, and wound complications [2][3]

Medical / Conservative Management

Medical therapy is indicated when surgery is declined, when the patient is a poor anesthetic candidate (e.g., advanced CKD, geriatric status), or as adjunctive therapy post-surgery [4]:

1. Dietary Management

• ·Frequent, small meals (every 4–6 hours) of a diet with a moderate glycemic index help prevent hypoglycemic nadirs [3]
• ·Avoidance of simple sugars that provoke rapid insulin release is recommended [3]
• ·In acute hypoglycemic crises, oral glucose supplementation (e.g., corn syrup applied to the oral mucosa) or intravenous dextrose is used [3]

2. Diazoxide

• ·Diazoxide is a benzothiadiazide derivative that inhibits insulin secretion from beta cells by opening ATP-sensitive potassium channels, and also stimulates hepatic gluconeogenesis [4]
• ·It has been used with success in cats unable to undergo surgery; one report describes effective glycemic stabilization in a 14-year-old cat with concurrent CKD (IRIS Stage 3–4) using diazoxide, enabling avoidance of high-risk surgery [4]
• ·Initial dosing typically starts at 5–10 mg/kg orally every 12 hours, with upward titration based on response; side effects may include vomiting, anorexia, and rarely sodium retention [4]

3. Glucocorticoids

• ·Prednisolone at anti-insulin doses (0.5–2 mg/kg/day) antagonizes insulin action and stimulates gluconeogenesis, providing a degree of glycemic support [3]
• ·Glucocorticoid use carries risks of iatrogenic diabetes mellitus, particularly in cats, and should be used judiciously [3]

4. Frequent Glucose Dextrose Supplementation (Acute Crises)

• ·Intravenous 50% dextrose diluted to 2.5–5% and administered as a constant rate infusion (CRI) is used for acute, severe hypoglycemic episodes [3]
• ·Care must be taken to avoid rapid glucose boluses that may paradoxically stimulate further insulin release [3]

5. Other Agents

• ·Octreotide (somatostatin analogue) has been used in dogs and humans to suppress insulin secretion but experience in cats is extremely limited
• ·Streptozotocin, used in canine insulinoma, is nephrotoxic and not well-characterized in cats

Monitoring

• ·Serial blood glucose monitoring (in-hospital and owner-performed) is essential throughout management [4]
• ·Periodic abdominal imaging (ultrasound or CT) to assess for disease progression or metastatic spread is recommended [2]

Overall Prognosis

Feline insulinoma carries a guarded to fair prognosis, with outcomes dependent on tumor stage, completeness of surgical resection, presence of metastases, and concurrent disease [2][3].

Surgical Outcomes — Key Data from the Literature

The largest published surgical series of feline insulinoma comprises 20 cats treated with surgical excision [2]:

• ·This retrospective study (2006–2020, multi-institutional) evaluated disease-free interval (DFI) and disease-related survival as primary outcome measures [2]
• ·Histopathological results and prognostic factors were analyzed, providing the most robust survival data currently available for this condition in cats [2]
• ·While the full survival statistics from this study are not available in the abstract, the cohort size and multi-year follow-up represent the current best evidence for surgical prognosis [2]

Individual Case Outcomes

• ·One cat treated with surgical excision of a left-lobe insulinoma achieved a survival time of at least 32 months post-operatively without recurrence [5]
• ·In a case managed medically with diazoxide (due to advanced CKD precluding surgery), the cat experienced meaningful glycemic control, though the underlying tumor remained in situ [4]
• ·A cat managed with a combination of dietary modification and surgical excision survived the perioperative period without major complications, though long-term follow-up in single case reports is limited [3]

Factors Affecting Prognosis

• ·Presence of metastatic disease at the time of surgery is expected to shorten DFI and overall survival, as in dogs and humans [2]
• ·Completeness of resection: Complete excision of all identifiable tumor tissue is associated with improved outcomes [2][3]
• ·Concurrent disease (e.g., CKD, which is prevalent in the older cat population most affected by insulinoma) significantly impacts anesthetic risk and treatment options [4]
• ·Malignant histology: Tumors classified as carcinoma rather than adenoma carry a worse long-term prognosis [2]
• ·Postoperative complications: Pancreatitis and new-onset diabetes mellitus following pancreatectomy can complicate recovery [2]

Important Limitation Note

Comprehensive survival statistics (median survival time, 1-year survival rates) specific to feline insulinoma are not yet well-established in the peer-reviewed literature due to the rarity of the condition and small case numbers. The study by Veytsman et al. (2023) [2] with 20 surgical cases represents the largest dataset to date, but full quantitative survival data were not available in the referenced abstract. Clinicians should interpret prognosis on an individualized basis. Data from canine insulinoma (where median survival times of 12–24 months post-surgery are reported) may provide a rough framework, but direct extrapolation to cats is not scientifically validated.

There are currently no known evidence-based strategies for the prevention of feline insulinoma, as the etiology of neoplastic beta-cell transformation in cats is not fully understood [1][7].

• ·No vaccine exists for insulinoma or any feline pancreatic neoplasm
• ·Genetic predisposition has not been characterized in cats, so breed-specific screening programs are not established
• ·Routine wellness bloodwork in middle-aged to senior cats (including fasting blood glucose as part of a standard biochemistry panel) may facilitate earlier detection of subclinical hypoglycemia, potentially allowing diagnosis before severe neurological episodes occur [2][3]
• ·Body weight management: While a direct causal link between obesity and feline insulinoma has not been proven, maintaining ideal body condition supports overall metabolic health
• ·Early veterinary evaluation of any older cat presenting with episodic weakness, seizures, or collapse is strongly recommended to allow timely diagnosis [3][5]
• ·Because insulinoma occurs predominantly in geriatric cats (mean age approximately 13–15 years in reported cases), increased clinical vigilance during routine senior wellness examinations is advisable [2][3][5]

In summary, prevention is not currently achievable with targeted measures; the emphasis lies on early detection through regular veterinary monitoring of at-risk (senior) cats.